TY - JOUR
T1 - Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
AU - Nouailles, Geraldine
AU - Adler, Julia M.
AU - Pennitz, Peter
AU - Peidli, Stefan
AU - Teixeira Alves, Luiz Gustavo
AU - Baumgardt, Morris
AU - Bushe, Judith
AU - Voss, Anne
AU - Langenhagen, Alina
AU - Langner, Christine
AU - Martin Vidal, Ricardo
AU - Pott, Fabian
AU - Kazmierski, Julia
AU - Ebenig, Aileen
AU - Lange, Mona V.
AU - Mühlebach, Michael D.
AU - Goekeri, Cengiz
AU - Simmons, Szandor
AU - Xing, Na
AU - Abdelgawad, Azza
AU - Herwig, Susanne
AU - Cichon, Günter
AU - Niemeyer, Daniela
AU - Drosten, Christian
AU - Goffinet, Christine
AU - Landthaler, Markus
AU - Blüthgen, Nils
AU - Wu, Haibo
AU - Witzenrath, Martin
AU - Gruber, Achim D.
AU - Praktiknjo, Samantha D.
AU - Osterrieder, Nikolaus
AU - Wyler, Emanuel
AU - Kunec, Dusan
AU - Trimpert, Jakob
PY - 2023/5
Y1 - 2023/5
N2 - Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines. © 2023, The Author(s).
AB - Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines. © 2023, The Author(s).
UR - http://www.scopus.com/inward/record.url?scp=85151465836&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85151465836&origin=recordpage
U2 - 10.1038/s41564-023-01352-8
DO - 10.1038/s41564-023-01352-8
M3 - RGC 21 - Publication in refereed journal
C2 - 37012419
SN - 2058-5276
VL - 8
SP - 860
EP - 874
JO - Nature Microbiology
JF - Nature Microbiology
ER -